JP2016507575A5 - - Google Patents

Download PDF

Info

Publication number
JP2016507575A5
JP2016507575A5 JP2015557226A JP2015557226A JP2016507575A5 JP 2016507575 A5 JP2016507575 A5 JP 2016507575A5 JP 2015557226 A JP2015557226 A JP 2015557226A JP 2015557226 A JP2015557226 A JP 2015557226A JP 2016507575 A5 JP2016507575 A5 JP 2016507575A5
Authority
JP
Japan
Prior art keywords
compound
compound according
formula
group
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015557226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507575A (ja
JP6471100B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/016100 external-priority patent/WO2014127042A1/en
Publication of JP2016507575A publication Critical patent/JP2016507575A/ja
Publication of JP2016507575A5 publication Critical patent/JP2016507575A5/ja
Application granted granted Critical
Publication of JP6471100B2 publication Critical patent/JP6471100B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015557226A 2013-02-12 2014-02-12 Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン Active JP6471100B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361763830P 2013-02-12 2013-02-12
US61/763,830 2013-02-12
PCT/US2014/016100 WO2014127042A1 (en) 2013-02-12 2014-02-12 Hydantoins that modulate bace-mediated app processing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019005905A Division JP6773820B2 (ja) 2013-02-12 2019-01-17 Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン

Publications (3)

Publication Number Publication Date
JP2016507575A JP2016507575A (ja) 2016-03-10
JP2016507575A5 true JP2016507575A5 (cg-RX-API-DMAC10.html) 2017-02-23
JP6471100B2 JP6471100B2 (ja) 2019-02-13

Family

ID=51354522

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015557226A Active JP6471100B2 (ja) 2013-02-12 2014-02-12 Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン
JP2019005905A Active JP6773820B2 (ja) 2013-02-12 2019-01-17 Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019005905A Active JP6773820B2 (ja) 2013-02-12 2019-01-17 Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン

Country Status (11)

Country Link
US (6) US10202355B2 (cg-RX-API-DMAC10.html)
EP (2) EP2956443B1 (cg-RX-API-DMAC10.html)
JP (2) JP6471100B2 (cg-RX-API-DMAC10.html)
KR (2) KR102051485B1 (cg-RX-API-DMAC10.html)
CN (1) CN104995176B (cg-RX-API-DMAC10.html)
AU (1) AU2014216390B2 (cg-RX-API-DMAC10.html)
CA (1) CA2899938C (cg-RX-API-DMAC10.html)
DK (1) DK2956443T3 (cg-RX-API-DMAC10.html)
ES (2) ES2975235T3 (cg-RX-API-DMAC10.html)
IL (1) IL240555B (cg-RX-API-DMAC10.html)
WO (1) WO2014127042A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202355B2 (en) 2013-02-12 2019-02-12 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
WO2016134042A2 (en) 2015-02-18 2016-08-25 Buck Institute For Research On Aging Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
CA3096896A1 (en) 2015-08-27 2017-03-02 Nantneuro, Llc 5,5'-disubstituted aminohydantoin compounds and compositions useful for inhibition of bace and the treatment of associated diseases
WO2017096049A1 (en) 2015-12-03 2017-06-08 The University Of North Carolina At Pembroke Materials for cathepsin b enhancement and methods of use
PT3503885T (pt) * 2016-08-19 2022-04-19 Foresee Pharmaceuticals Co Ltd Composição farmacêutica e métodos de utilização
US10532102B2 (en) 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
CN107468690B (zh) 2017-08-11 2020-01-31 北京卓凯生物技术有限公司 4-氧-烷基化特特拉姆酸类化合物及其制备方法与应用
CN107353239B (zh) * 2017-08-11 2019-06-18 北京卓凯生物技术有限公司 4-氧-烷基化特特拉姆酸类化合物及其制备方法
EP3759079A4 (en) * 2018-03-01 2021-11-17 The Regents Of The University Of California AMYLOID PROTEIN SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER'S DISEASE
CN110652516A (zh) * 2018-06-29 2020-01-07 上海绿谷制药有限公司 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用
CN113412089A (zh) * 2018-12-04 2021-09-17 脑部保护私人有限公司 包括用于治疗病症的可植入阻尼装置和治疗剂的组合疗法及相关系统和使用方法
EP3890619A1 (en) 2018-12-04 2021-10-13 The Brain Protection Company PTY Ltd Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use
US11926599B1 (en) 2023-10-23 2024-03-12 King Faisal University 1-(2-chlorobenzylideneamino)-5,5-diphenylimidazolidine-2,4-dione as an antimicrobial compound

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4995971A (cg-RX-API-DMAC10.html) * 1973-01-27 1974-09-11
DE2448869A1 (de) 1973-10-19 1975-09-04 Mcneilab Inc 4-oxo-2-imidazolidinylidenharnstoffe, verfahren zu ihrer herstellung und arzneimittel
US4025517A (en) * 1975-06-23 1977-05-24 Mcneil Laboratories, Incorporated 4-Oxo-2-hexahydropyrimidinylidene ureas
JPS554305A (en) * 1978-06-13 1980-01-12 Nippon Zoki Pharmaceut Co Ltd Remedy for disease caused by stress and its preparation
US5070100A (en) 1983-09-14 1991-12-03 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives
US4864028A (en) * 1983-09-14 1989-09-05 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
CH677886A5 (cg-RX-API-DMAC10.html) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
WO1991019810A1 (en) 1990-06-15 1991-12-26 California Biotechnology Inc. Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
EP0568575B2 (en) 1991-01-21 2010-11-03 Elan Pharmaceuticals, Inc. Test and model for alzheimer's disease
AU671093B2 (en) 1992-01-07 1996-08-15 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
CA2174429C (en) 1993-10-27 2011-08-30 Lisa C. Mcconlogue Transgenic animals harboring app allele having swedish mutation
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
FR2730932B1 (fr) 1995-02-27 1997-04-04 Oreal Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
AU6383396A (en) 1995-06-07 1996-12-30 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
FR2742676B1 (fr) 1995-12-21 1998-02-06 Oreal Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie
FR2755854B1 (fr) 1996-11-15 1998-12-24 Oreal Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations
FR2760970B1 (fr) 1997-03-18 2000-03-10 Oreal Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations
WO2000003819A1 (en) 1998-07-17 2000-01-27 The Penn State Research Foundation Full form roll finishing technique
CN1502692A (zh) 1998-09-24 2004-06-09 �������Ŷ���Լ��������˾ 阿尔茨海默氏疾病分泌酶
FR2787026B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters mixtes d'acide gras ou d'alcool gras, d'acide carboxylique et de glyceryle, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787027B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787325B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787326B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787728B1 (fr) 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2787703B1 (fr) 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788007B1 (fr) 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788449B1 (fr) 1999-01-14 2001-02-16 Oreal Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2789076B1 (fr) 1999-02-02 2001-03-02 Synthelabo Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique
US7161962B1 (en) 1999-05-27 2007-01-09 Nuera Communications, Inc. Method and apparatus for coding modem signals for transmission over voice networks
FR2811564B1 (fr) 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
EP1425311A4 (en) 2001-01-11 2004-12-01 Eastman Chem Co CYCLODEXTRINSULFONATES, GUEST INCLUDING COMPLEXES, METHOD FOR THEIR PRODUCTION AND RELATED MATERIALS
FR2819427B1 (fr) 2001-01-18 2003-04-11 Oreal Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
WO2004030608A2 (en) 2001-06-05 2004-04-15 The Regents Of The University Of Michigan Nanoemulsion vaccines
US7476393B2 (en) 2002-11-29 2009-01-13 L'oreal Process for the preparation of a cationic nanoemulsion, and cosmetic composition
KR20060056376A (ko) 2003-08-08 2006-05-24 쉐링 코포레이션 헤테로사이클릭 치환체를 갖는 사이클릭 아민 ｂａｃｅ-1 억제제
CN1863797A (zh) 2003-08-08 2006-11-15 先灵公司 具有苯甲酰胺取代基的环胺bace－1抑制剂
MY149978A (en) 2003-12-15 2013-11-15 Merck Sharp & Dohme Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7468402B2 (en) 2004-03-17 2008-12-23 Baker Hughes Incorporated Polymeric nanoemulsion as drag reducer for multiphase flow
JP2008502880A (ja) 2004-04-02 2008-01-31 メルク　エンド　カムパニー　インコーポレーテッド アミロイド前駆体タンパク質又はβアミロイド断片に結合する物質を検出する方法及び結合化合物
EP1740573A1 (en) 2004-04-22 2007-01-10 Eli Lilly And Company Amides as bace inhibitors
IL162288A0 (en) 2004-06-01 2005-11-20 Future Products Man S A Compositions and methods for treating neurodegenerative disorders
EP1756087B1 (en) 2004-06-16 2009-10-07 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
JP2008503460A (ja) 2004-06-16 2008-02-07 ワイス β−セクレターゼのインヒビターとしてのジフェニルイミダゾピリミジンおよびイミダゾールアミン
MX2007000760A (es) 2004-07-22 2007-04-09 Schering Corp Amida sustituida inhibidora de b secretasa.
ATE396990T1 (de) 2004-07-28 2008-06-15 Schering Corp Makrocyclische inhibitoren der beta-sekretase
PE20060692A1 (es) 2004-09-21 2006-07-19 Lilly Co Eli Inhibidores bace
GB0500683D0 (en) 2005-01-13 2005-02-23 Novartis Ag Organic compounds
RU2007130794A (ru) 2005-01-13 2009-02-20 Новартис АГ (CH) Макроциклические соединения для применения в качестве ингибиторов bace
CA2610617A1 (en) 2005-06-14 2006-12-28 Schering Corporation The preparation and use of protease inhibitors
EP1891021B1 (en) 2005-06-14 2019-01-23 Merck Sharp & Dohme Corp. Aspartyl protease inhibitors
US8110682B2 (en) 2005-06-14 2012-02-07 Schering Corporation Preparation and use of compounds as aspartyl protease inhibitors
US7812013B2 (en) 2005-06-14 2010-10-12 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
WO2006138192A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
AU2006259572A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
US8722708B2 (en) 2005-06-14 2014-05-13 Merck Sharp & Dohme Inc. Substituted isoindolines as aspartyl protease inhibitors
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
JP2009500329A (ja) 2005-06-30 2009-01-08 ワイス アミノ−５−（６員）ヘテロアリールイミダゾロン化合物およびβ−セレクターゼ調節のためのその使用
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
CN101273018A (zh) 2005-09-26 2008-09-24 惠氏公司 用于β分泌酶（BACE）抑制剂的氨基-5-[4-(二氟甲氧基)苯基]-5-苯基咪唑酮化合物
DE602006016314D1 (de) 2005-10-27 2010-09-30 Schering Corp Heterozyklische aspartyl-proteasehemmer
WO2007053506A1 (en) 2005-10-31 2007-05-10 Schering Corporation Aspartyl protease inhibitors
WO2007058601A1 (en) 2005-11-21 2007-05-24 Astrazeneca Ab Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia
GB0602951D0 (en) 2006-02-14 2006-03-29 Novartis Ag Organic Compounds
EP2004630A4 (en) 2006-04-05 2010-05-19 Astrazeneca Ab 2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF PATHOLOGIES RELATED TO PROTEIN A
GB0611064D0 (en) 2006-06-05 2006-07-12 Novartis Ag Organic compounds
KR20090015967A (ko) 2006-06-12 2009-02-12 쉐링 코포레이션 헤테로사이클릭 아스파르틸 프로테아제 억제제
TW200815449A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds II
TW200815443A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
TW200808796A (en) 2006-06-14 2008-02-16 Astrazeneca Ab New compounds III
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
KR20090039726A (ko) 2006-07-20 2009-04-22 노파르티스 아게 Ｂａｃｅ 억제제로서 유용한 마크로시클릭 화합물
RU2009105764A (ru) 2006-07-20 2010-08-27 Новартис АГ (CH) Макроциклические соединения, применимые в качестве ингибиторов васе
BRPI0719336A2 (pt) 2006-11-23 2014-02-04 Novartis Ag Derivados de 2-hidróxi-1,3-diaminopropano
EP2061771A1 (en) 2006-12-12 2009-05-27 Schering Corporation Aspartyl protease inhibitors containing a tricyclic ring system
CA2672293A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
JP2010521457A (ja) * 2007-03-12 2010-06-24 メルク・シャープ・エンド・ドーム・コーポレイション 単環式アニリドスピロラクタムｃｇｒｐ受容体アンタゴニスト
PE20090160A1 (es) * 2007-03-20 2009-02-11 Wyeth Corp COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
US20090041201A1 (en) 2007-08-06 2009-02-12 Carestream Health, Inc. Alignment apparatus for imaging system
MX2010002007A (es) 2007-08-23 2010-03-10 Novartis Ag Sulfonas ciclicas sustituidas por amino-bencilo utiles como inhibidores de bace.
US20090062361A1 (en) 2007-08-30 2009-03-05 Allergan, Inc. Therapeutic hydantoins
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
JP2011527311A (ja) 2008-07-10 2011-10-27 ノバルティス アーゲー Ｂａｃｅ阻害薬として有用なアミノベンジル置換環状スルホン誘導体
CN102186841A (zh) 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
BRPI0823254A2 (pt) 2008-11-11 2015-06-23 Inst Materia Medica Cams Complexos de inclusão de pinocembrina com ciclodextrina ou seus derivados
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2012024616A1 (en) 2010-08-19 2012-02-23 Buck Institute For Age Research Methods of treating miild cognitive impairment (mci) and related discorders
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US20120165346A1 (en) 2010-12-22 2012-06-28 Astrazeneca Ab Compounds and their use as BACE inhibitors
US8877744B2 (en) 2011-04-04 2014-11-04 Hoffmann-La Roche Inc. 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
US10202355B2 (en) 2013-02-12 2019-02-12 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
CA3096896A1 (en) * 2015-08-27 2017-03-02 Nantneuro, Llc 5,5'-disubstituted aminohydantoin compounds and compositions useful for inhibition of bace and the treatment of associated diseases

Similar Documents

Publication Publication Date Title
JP2016507575A5 (cg-RX-API-DMAC10.html)
JP2013537203A5 (cg-RX-API-DMAC10.html)
JP2016505614A5 (cg-RX-API-DMAC10.html)
JP2016506962A5 (cg-RX-API-DMAC10.html)
JP2016515561A5 (cg-RX-API-DMAC10.html)
JP2010511721A5 (cg-RX-API-DMAC10.html)
JP2017509586A5 (cg-RX-API-DMAC10.html)
JP2016040288A5 (cg-RX-API-DMAC10.html)
JP2015512931A5 (cg-RX-API-DMAC10.html)
JP2017504611A5 (cg-RX-API-DMAC10.html)
JP2015508749A5 (cg-RX-API-DMAC10.html)
JP2011519956A5 (ja) キナゾリン誘導体及び同キナゾリン誘導体を含む治療薬
JP2013533879A5 (cg-RX-API-DMAC10.html)
JP2012508252A5 (cg-RX-API-DMAC10.html)
JP2014525420A5 (cg-RX-API-DMAC10.html)
JP2020097577A5 (cg-RX-API-DMAC10.html)
JP2016503797A5 (cg-RX-API-DMAC10.html)
JP2016516043A5 (cg-RX-API-DMAC10.html)
JP2016506961A5 (cg-RX-API-DMAC10.html)
JP2012041349A5 (cg-RX-API-DMAC10.html)
JP2016531126A5 (cg-RX-API-DMAC10.html)
JP2011513410A5 (cg-RX-API-DMAC10.html)
JP2016130266A5 (cg-RX-API-DMAC10.html)
JP2016504400A5 (cg-RX-API-DMAC10.html)
JP2018515563A5 (cg-RX-API-DMAC10.html)